Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

National Neuroinformatics Framework for Canadian Consortium on Neurodegeneration in Aging (CCNA).

Mohaddes Z, Das S, Abou-Haidar R, Safi-Harab M, Blader D, Callegaro J, Henri-Bellemare C, Tunteng JF, Evans L, Campbell T, Lo D, Morin PE, Whitehead V, Chertkow H, Evans AC.

Front Neuroinform. 2018 Dec 21;12:85. doi: 10.3389/fninf.2018.00085. eCollection 2018.

2.

Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

Li J, Kennedy LJ, Walker SJ, Wang H, Li JJ, Hong Z, O'Connor SP, Ye XY, Chen S, Wu S, Yoon DS, Nayeem A, Camac DM, Ramamurthy V, Morin PE, Sheriff S, Wang M, Harper TW, Golla R, Seethala R, Harrity T, Ponticiello RP, Morgan NN, Taylor JR, Zebo R, Maxwell B, Moulin F, Gordon DA, Robl JA.

ACS Med Chem Lett. 2018 Nov 13;9(12):1170-1174. doi: 10.1021/acsmedchemlett.8b00307. eCollection 2018 Dec 13.

PMID:
30613321
3.

Osteoporosis-Related Health Services Utilization Following First Hip Fracture Among a Cohort of Privately-Insured Women in the United States, 2008-2014: An Observational Study.

Gillespie CW, Morin PE.

J Bone Miner Res. 2018 Mar;33(3):549. doi: 10.1002/jbmr.3366. Epub 2018 Feb 2. No abstract available.

4.

Costs and Trends in Utilization of Low-value Services Among Older Adults With Commercial Insurance or Medicare Advantage.

Carter EA, Morin PE, Lind KD.

Med Care. 2017 Nov;55(11):931-939. doi: 10.1097/MLR.0000000000000809.

PMID:
28930892
5.

Radiosynthesis and preclinical PET evaluation of 89Zr-nivolumab (BMS-936558) in healthy non-human primates.

Cole EL, Kim J, Donnelly DJ, Smith RA, Cohen D, Lafont V, Morin PE, Huang RY, Chow PL, Hayes W, Bonacorsi S Jr.

Bioorg Med Chem. 2017 Oct 15;25(20):5407-5414. doi: 10.1016/j.bmc.2017.07.066. Epub 2017 Aug 4.

PMID:
28803798
6.

Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor.

Ye XY, Chen SY, Wu S, Yoon DS, Wang H, Hong Z, O'Connor SP, Li J, Li JJ, Kennedy LJ, Walker SJ, Nayeem A, Sheriff S, Camac DM, Ramamurthy V, Morin PE, Zebo R, Taylor JR, Morgan NN, Ponticiello RP, Harrity T, Apedo A, Golla R, Seethala R, Wang M, Harper TW, Sleczka BG, He B, Kirby M, Leahy DK, Li J, Hanson RL, Guo Z, Li YX, DiMarco JD, Scaringe R, Maxwell B, Moulin F, Barrish JC, Gordon DA, Robl JA.

J Med Chem. 2017 Jun 22;60(12):4932-4948. doi: 10.1021/acs.jmedchem.7b00211. Epub 2017 Jun 5.

PMID:
28537398
7.
8.

Trends and Disparities in Osteoporosis Screening Among Women in the United States, 2008-2014.

Gillespie CW, Morin PE.

Am J Med. 2017 Mar;130(3):306-316. doi: 10.1016/j.amjmed.2016.10.018. Epub 2016 Nov 21.

9.

Observation Status or Inpatient Admission: Impact of Patient Disposition on Outcomes and Utilization Among Emergency Department Patients With Chest Pain.

Bellolio MF, Sangaralingham LR, Schilz SR, Noel-Miller CM, Lind KD, Morin PE, Noseworthy PA, Shah ND, Hess EP.

Acad Emerg Med. 2017 Feb;24(2):152-160. doi: 10.1111/acem.13116.

10.

Novel phenylalanine derived diamides as Factor XIa inhibitors.

Smith LM 2nd, Orwat MJ, Hu Z, Han W, Wang C, Rossi KA, Gilligan PJ, Pabbisetty KB, Osuna H, Corte JR, Rendina AR, Luettgen JM, Wong PC, Narayanan R, Harper TW, Bozarth JM, Crain EJ, Wei A, Ramamurthy V, Morin PE, Xin B, Zheng J, Seiffert DA, Quan ML, Lam PYS, Wexler RR, Pinto DJP.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):472-478. doi: 10.1016/j.bmcl.2015.11.089. Epub 2015 Nov 26.

PMID:
26704266
11.

Discovery of novel P1 groups for coagulation factor VIIa inhibition using fragment-based screening.

Cheney DL, Bozarth JM, Metzler WJ, Morin PE, Mueller L, Newitt JA, Nirschl AH, Rendina AR, Tamura JK, Wei A, Wen X, Wurtz NR, Seiffert DA, Wexler RR, Priestley ES.

J Med Chem. 2015 Mar 26;58(6):2799-808. doi: 10.1021/jm501982k. Epub 2015 Mar 12.

PMID:
25764119
12.

Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.

Pinto DJ, Smallheer JM, Corte JR, Austin EJ, Wang C, Fang T, Smith LM 2nd, Rossi KA, Rendina AR, Bozarth JM, Zhang G, Wei A, Ramamurthy V, Sheriff S, Myers JE Jr, Morin PE, Luettgen JM, Seiffert DA, Quan ML, Wexler RR.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1635-42. doi: 10.1016/j.bmcl.2015.01.028. Epub 2015 Feb 4.

PMID:
25728130
13.

Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics.

Iacob RE, Krystek SR, Huang RY, Wei H, Tao L, Lin Z, Morin PE, Doyle ML, Tymiak AA, Engen JR, Chen G.

Expert Rev Proteomics. 2015 Apr;12(2):159-69. doi: 10.1586/14789450.2015.1018897. Epub 2015 Feb 24. Review.

14.

Pyridine and pyridinone-based factor XIa inhibitors.

Corte JR, Fang T, Hangeland JJ, Friends TJ, Rendina AR, Luettgen JM, Bozarth JM, Barbera FA, Rossi KA, Wei A, Ramamurthy V, Morin PE, Seiffert DA, Wexler RR, Quan ML.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):925-30. doi: 10.1016/j.bmcl.2014.12.050. Epub 2014 Dec 31.

PMID:
25592713
15.

Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.

Hangeland JJ, Friends TJ, Rossi KA, Smallheer JM, Wang C, Sun Z, Corte JR, Fang T, Wong PC, Rendina AR, Barbera FA, Bozarth JM, Luettgen JM, Watson CA, Zhang G, Wei A, Ramamurthy V, Morin PE, Bisacchi GS, Subramaniam S, Arunachalam P, Mathur A, Seiffert DA, Wexler RR, Quan ML.

J Med Chem. 2014 Dec 11;57(23):9915-32. doi: 10.1021/jm5010607. Epub 2014 Dec 2.

PMID:
25405503
16.

The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.

Iacob RE, Chen G, Ahn J, Houel S, Wei H, Mo J, Tao L, Cohen D, Xie D, Lin Z, Morin PE, Doyle ML, Tymiak AA, Engen JR.

J Am Soc Mass Spectrom. 2014 Dec;25(12):2093-102. doi: 10.1007/s13361-014-0973-1. Epub 2014 Sep 16.

17.

Optimization of 1,2,4-Triazolopyridines as Inhibitors of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1).

Li J, Kennedy LJ, Wang H, Li JJ, Walker SJ, Hong Z, O'Connor SP, Nayeem A, Camac DM, Morin PE, Sheriff S, Wang M, Harper T, Golla R, Seethala R, Harrity T, Ponticiello RP, Morgan NN, Taylor JR, Zebo R, Gordon DA, Robl JA.

ACS Med Chem Lett. 2014 May 22;5(7):803-8. doi: 10.1021/ml500144h. eCollection 2014 Jul 10.

18.

Reactive metabolite trapping screens and potential pitfalls: bioactivation of a homomorpholine and formation of an unstable thiazolidine adduct.

Lenz EM, Martin S, Schmidt R, Morin PE, Smith R, Weston DJ, Bayrakdarian M.

Chem Res Toxicol. 2014 Jun 16;27(6):968-80. doi: 10.1021/tx5000409. Epub 2014 Jun 5.

PMID:
24855970
19.

Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.

Quan ML, Wong PC, Wang C, Woerner F, Smallheer JM, Barbera FA, Bozarth JM, Brown RL, Harpel MR, Luettgen JM, Morin PE, Peterson T, Ramamurthy V, Rendina AR, Rossi KA, Watson CA, Wei A, Zhang G, Seiffert D, Wexler RR.

J Med Chem. 2014 Feb 13;57(3):955-69. doi: 10.1021/jm401670x. Epub 2014 Jan 17.

PMID:
24405333
20.

Discovery and preclinical characterization of the cyclopropylindolobenzazepine BMS-791325, a potent allosteric inhibitor of the hepatitis C virus NS5B polymerase.

Gentles RG, Ding M, Bender JA, Bergstrom CP, Grant-Young K, Hewawasam P, Hudyma T, Martin S, Nickel A, Regueiro-Ren A, Tu Y, Yang Z, Yeung KS, Zheng X, Chao S, Sun JH, Beno BR, Camac DM, Chang CH, Gao M, Morin PE, Sheriff S, Tredup J, Wan J, Witmer MR, Xie D, Hanumegowda U, Knipe J, Mosure K, Santone KS, Parker DD, Zhuo X, Lemm J, Liu M, Pelosi L, Rigat K, Voss S, Wang Y, Wang YK, Colonno RJ, Gao M, Roberts SB, Gao Q, Ng A, Meanwell NA, Kadow JF.

J Med Chem. 2014 Mar 13;57(5):1855-79. doi: 10.1021/jm4016894. Epub 2014 Jan 7.

PMID:
24397558
21.

Discovery of 3-hydroxy-4-cyano-isoquinolines as novel, potent, and selective inhibitors of human 11β-hydroxydehydrogenase 1 (11β-HSD1).

Wu SC, Yoon D, Chin J, van Kirk K, Seethala R, Golla R, He B, Harrity T, Kunselman LK, Morgan NN, Ponticiello RP, Taylor JR, Zebo R, Harper TW, Li W, Wang M, Zhang L, Sleczka BG, Nayeem A, Sheriff S, Camac DM, Morin PE, Everlof JG, Li YX, Ferraro CA, Kieltyka K, Shou W, Vath MB, Zvyaga TA, Gordon DA, Robl JA.

Bioorg Med Chem Lett. 2011 Nov 15;21(22):6693-8. doi: 10.1016/j.bmcl.2011.09.058. Epub 2011 Sep 21.

PMID:
21983444
22.

Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1.

Marcin LR, Higgins MA, Zusi FC, Zhang Y, Dee MF, Parker MF, Muckelbauer JK, Camac DM, Morin PE, Ramamurthy V, Tebben AJ, Lentz KA, Grace JE, Marcinkeviciene JA, Kopcho LM, Burton CR, Barten DM, Toyn JH, Meredith JE, Albright CF, Bronson JJ, Macor JE, Thompson LA.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):537-41. doi: 10.1016/j.bmcl.2010.10.079.

PMID:
21078556
23.

Delta agonist hydroxy bioisosteres: the discovery of 3-((1-benzylpiperidin-4-yl){4-[(diethylamino)carbonyl]phenyl}amino)benzamide with improved delta agonist activity and in vitro metabolic stability.

Griffin AM, Brown W, Walpole C, Coupal M, Adam L, Gosselin M, Salois D, Morin PE, Roumi M.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):5999-6003. doi: 10.1016/j.bmcl.2009.09.068. Epub 2009 Sep 22.

PMID:
19800790
24.

Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Wang H, Ruan Z, Li JJ, Simpkins LM, Smirk RA, Wu SC, Hutchins RD, Nirschl DS, Van Kirk K, Cooper CB, Sutton JC, Ma Z, Golla R, Seethala R, Salyan ME, Nayeem A, Krystek SR Jr, Sheriff S, Camac DM, Morin PE, Carpenter B, Robl JA, Zahler R, Gordon DA, Hamann LG.

Bioorg Med Chem Lett. 2008 Jun 1;18(11):3168-72. doi: 10.1016/j.bmcl.2008.04.069. Epub 2008 May 1.

PMID:
18485702
25.

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.

Corte JR, Fang T, Pinto DJ, Han W, Hu Z, Jiang XJ, Li YL, Gauuan JF, Hadden M, Orton D, Rendina AR, Luettgen JM, Wong PC, He K, Morin PE, Chang CH, Cheney DL, Knabb RM, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2008 May 1;18(9):2845-9. doi: 10.1016/j.bmcl.2008.03.092. Epub 2008 Apr 8.

PMID:
18424044
26.

Comparison of sub-2-microm particle columns for fast metabolite ID.

Walles M, Gauvin C, Morin PE, Panetta R, Ducharme J.

J Sep Sci. 2007 May;30(8):1191-9.

PMID:
17595954
27.

SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.

Qiao JX, Chang CH, Cheney DL, Morin PE, Wang GZ, King SR, Wang TC, Rendina AR, Luettgen JM, Knabb RM, Wexler RR, Lam PY.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4419-27. Epub 2007 Jun 10.

PMID:
17588746
28.
29.

Comparative studies of active site-ligand interactions among various recombinant constructs of human beta-amyloid precursor protein cleaving enzyme.

Kopcho LM, Ma J, Marcinkeviciene J, Lai Z, Witmer MR, Cheng J, Yanchunas J, Tredup J, Corbett M, Calambur D, Wittekind M, Paruchuri M, Kothari D, Lee G, Ganguly S, Ramamurthy V, Morin PE, Camac DM, King RW, Lasut AL, Ross OH, Hillman MC, Fish B, Shen K, Dowling RL, Kim YB, Graciani NR, Collins D, Combs AP, George H, Thompson LA, Copeland RA.

Arch Biochem Biophys. 2003 Feb 15;410(2):307-16.

PMID:
12573291
30.

N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.

Wei ZY, Brown W, Takasaki B, Plobeck N, Delorme D, Zhou F, Yang H, Jones P, Gawell L, Gagnon H, Schmidt R, Yue SY, Walpole C, Payza K, St-Onge S, Labarre M, Godbout C, Jakob A, Butterworth J, Kamassah A, Morin PE, Projean D, Ducharme J, Roberts E.

J Med Chem. 2000 Oct 19;43(21):3895-905.

PMID:
11052794
31.

New diarylmethylpiperazines as potent and selective nonpeptidic delta opioid receptor agonists with increased In vitro metabolic stability.

Plobeck N, Delorme D, Wei ZY, Yang H, Zhou F, Schwarz P, Gawell L, Gagnon H, Pelcman B, Schmidt R, Yue SY, Walpole C, Brown W, Zhou E, Labarre M, Payza K, St-Onge S, Kamassah A, Morin PE, Projean D, Ducharme J, Roberts E.

J Med Chem. 2000 Oct 19;43(21):3878-94.

PMID:
11052793
32.

Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor.

Nicoll-Griffith DA, Falgueyret JP, Silva JM, Morin PE, Trimble L, Chan CC, Clas S, Leger S, Wang Z, Yergey JA, Riendeau D.

Drug Metab Dispos. 1999 Mar;27(3):403-9.

PMID:
10064573
33.

Yeast transcript elongation factor (TFIIS), structure and function. I: NMR structural analysis of the minimal transcriptionally active region.

Olmsted VK, Awrey DE, Koth C, Shan X, Morin PE, Kazanis S, Edwards AM, Arrowsmith CH.

J Biol Chem. 1998 Aug 28;273(35):22589-94.

34.

Refinement of an in vitro cell model for cytochrome P450 induction.

Silva JM, Morin PE, Day SH, Kennedy BP, Payette P, Rushmore T, Yergey JA, Nicoll-Griffith DA.

Drug Metab Dispos. 1998 May;26(5):490-6.

PMID:
9571231
35.

Elongation factor TFIIS contains three structural domains: solution structure of domain II.

Morin PE, Awrey DE, Edwards AM, Arrowsmith CH.

Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10604-8.

36.

Mass spectrometric characterization of sequence-specific complexes of DNA and transcription factor PU.1 DNA binding domain.

Cheng X, Morin PE, Harms AC, Bruce JE, Ben-David Y, Smith RD.

Anal Biochem. 1996 Jul 15;239(1):35-40.

PMID:
8660622
37.

Refolding of bovine pancreatic trypsin inhibitor via non-native disulphide intermediates.

Darby NJ, Morin PE, Talbo G, Creighton TE.

J Mol Biol. 1995 Jun 2;249(2):463-77.

PMID:
7540214
38.

Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor.

Johnson CR, Morin PE, Arrowsmith CH, Freire E.

Biochemistry. 1995 Apr 25;34(16):5309-16.

PMID:
7727392
39.

Direct calorimetric analysis of the enzymatic activity of yeast cytochrome c oxidase.

Morin PE, Freire E.

Biochemistry. 1991 Aug 27;30(34):8494-500.

PMID:
1653014
40.

Thermal stability of membrane-reconstituted yeast cytochrome c oxidase.

Morin PE, Diggs D, Freire E.

Biochemistry. 1990 Jan 23;29(3):781-8.

PMID:
2159790

Supplemental Content

Loading ...
Support Center